| Expression pattern: |
UP |
| Associated gene: |
GPRC5A, EGFR, PCNA, BCL-2 |
| Associated microRNA: |
miR-195 |
| Biological function: |
promotes gastric cancer cell viability and proliferation, promotes migration/invasion and tumour growth, and inhibits apoptosis |
| Molecular mechanism: |
hsa_circ_006100 targets/inhibits miR-195 and modulates the miR-195 target GPRC5A, involving GPRC5A/EGFR signaling and EMT phenotype changes |
| Biological pathway or process: |
proliferation (promotes); apoptosis (inhibits); migration (promotes); invasion (promotes); metastasis (promotes); EMT (promotes); EGFR (promotes); ceRNA regulation (promotes) |
| Detected method: |
Q
S
|
| Validation methods: |
RNA-seq; RT-qPCR; Bioinformatics Analysis; Luciferase Reporter Assay; Transfection; CCK8; Colony Formation Assay; Transwell Assay; In Vivo Animal Model; Western Blot; IHC (Immunohistochemistry); Clinical Sample Validation; Cohort Study |
| Clinical significance: |
High hsa_circ_006100 expression was associated with advanced TNM stage, poor differentiation, lymph node metastasis and worse clinical outcomes. |
| Description: |
hsa_circ_006100 is up-regulated in gastric cancer tissues and cell lines and acts as an oncogenic circRNA. It inhibits miR-195 and thereby derepresses the miR-195 target GPRC5A (with involvement of EGFR signaling), promoting proliferation and migration/invasion and enhancing EMT-related changes; knockdown suppresses xenograft tumour growth. |
| Confidence score: |
0.7628 |